ストックスクリーナーアプリを入手
8.86
1.72%
0.16
前日終値:
$8.70
開ける：
$8.66
24時間の取引高:
426.27K
Relative Volume:
0.20
時価総額：
$1.53B
収益：
$25.55M
当期純損益:
$-341.97M
株価収益率:
-3.1643
EPS:
-2.8
ネットキャッシュフロー:
$-304.44M
1週間 パフォーマンス:
-0.90%
1か月 パフォーマンス:
+19.11%
6か月 パフォーマンス:
+139.84%
1年 パフォーマンス:
+125.77%
1日の値動き範囲:
$8.645
$9.005
1週間の範囲:
$8.42
$9.43
52週間の値動き範囲:
$1.775
$9.54
Relay Therapeutics Inc Stock (RLAY) Company Profile
Compare RLAY vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
8.855 | 1.51B | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.83 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.69 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.96 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-26 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-12-12 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-04-17 | 開始されました | Wells Fargo | Equal Weight |
| 2024-09-10 | 再開されました | Goldman | Buy |
| 2024-09-10 | アップグレード | Jefferies | Hold → Buy |
| 2024-09-10 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-05-10 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-04-20 | アップグレード | Jefferies | Underperform → Hold |
| 2023-04-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 開始されました | Raymond James | Outperform |
| 2023-02-03 | 開始されました | Oppenheimer | Outperform |
| 2022-09-30 | 開始されました | Barclays | Equal Weight |
| 2022-09-02 | 開始されました | Stifel | Buy |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-02-01 | 開始されました | Berenberg | Buy |
| 2021-07-21 | 開始されました | BofA Securities | Buy |
| 2020-12-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-11-05 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-10 | 開始されました | Cowen | Outperform |
| 2020-08-10 | 開始されました | Goldman | Buy |
| 2020-08-10 | 開始されました | Guggenheim | Buy |
| 2020-08-10 | 開始されました | JP Morgan | Neutral |
すべてを表示
Relay Therapeutics Inc (RLAY) 最新ニュース
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million - The Motley Fool
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Could a 65.91% Upside Potential Spark Investor Interest? - DirectorsTalk Interviews
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 - The Manila Times
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - Quiver Quantitative
Relay Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Investment Report: Is HEES stock suitable for long term investingPortfolio Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
Relay earnings in focus as FDA breakthrough fuels optimism By Investing.com - Investing.com Australia
Relay Therapeutics (RLAY) to Release Quarterly Earnings on Wednesday - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Trend Review: Will Relay Therapeutics Inc. benefit from government policyWeekly Investment Recap & AI Powered Market Entry Strategies - mfd.ru
Can Relay Therapeutics Inc. expand its profit marginsPortfolio Update Report & Weekly Watchlist of Top Performers - mfd.ru
Relay Therapeutics, Inc. (RLAY) Stock Analysis: 71% Upside Potential as Analysts Show Strong Buy Confidence - DirectorsTalk Interviews
Can Relay Therapeutics Inc. sustain its profitability2025 Bull vs Bear & Low Risk High Reward Trade Ideas - mfd.ru
Relay Therapeutics stock hits 52-week high at $9.16 By Investing.com - Investing.com Australia
Relay Therapeutics (NASDAQ:RLAY) Sets New 12-Month HighTime to Buy? - MarketBeat
Relay Therapeutics stock hits 52-week high at $9.16 - Investing.com
Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount - Sahm
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib - Yahoo Finance
Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run - The Globe and Mail
$207B Market Shift: The Race for Fast Track Approval in Oncology - Investing News Network
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Relay Thera’s zovegalisib wins ‘Breakthrough’ status from FDA - The Pharma Letter
Relay Therapeutics announces Zovegalisib granted therapy designation by FDA for PIK3CA-mutant - marketscreener.com
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status By Investing.com - Investing.com South Africa
Relay Therapeutics stock rises after FDA grants Breakthrough Therapy status - Investing.com
Relay Therapeutics Announces Breakthrough Therapy Designation for Zovegalisib - TradingView
Relay Therapeutics Announces Zovegalisib Granted - GlobeNewswire
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer - The Manila Times
Aug Retail: Can Relay Therapeutics Inc sustain its profitabilityProfit Target & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Finviz
Relay Therapeutics (NASDAQ:RLAY) Shares Up 7.2%Here's Why - MarketBeat
Oppenheimer Notes Relay Therapeutics (RLAY) Pipeline Strength in Mutant-Selective Inhibitors - Yahoo Finance
What Relay Therapeutics (RLAY)'s Zovegalisib Data and Insider Sales Mean For Shareholders - Sahm
Rate Cut: Is Relay Therapeutics Inc a speculative investmentPortfolio Gains Report & Consistent Profit Alerts - baoquankhu1.vn
Movement Recap: Will Relay Therapeutics Inc benefit from government policyWeekly Profit Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring an 88.66% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Relay Therapeutics (RLAY) Valuation Check After Analyst Upgrades And Zovegalisib Breast Cancer Data - Sahm
Relay Therapeutics president sells $166k in RLAY stock By Investing.com - Investing.com Australia
Moving Averages: Is Trex Company Inc stock a buy or sellTrade Analysis Summary & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Guidance Update: Can Relay Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Relay Therapeutics (NASDAQ:RLAY) Insider Donald Bergstrom Sells 2,686 Shares - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Insider Sells $11,441.30 in Stock - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) CFO Sells 1,695 Shares of Stock - MarketBeat
Insider Selling: Relay Therapeutics (NASDAQ:RLAY) Insider Sells 11,684 Shares of Stock - MarketBeat
Thomas Catinazzo Sells 13,820 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock - MarketBeat
Rahmer Peter, chief corporate development officer at Relay Therapeutics, sells $100k in shares - Investing.com Canada
Relay Therapeutics president sells $166k in RLAY stock - Investing.com
Relay Therapeutics Inc (RLAY) 財務データ
収益
当期純利益
現金流量
EPS
Relay Therapeutics Inc (RLAY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bergstrom Donald A | President, R&D |
Jan 28 '26 |
Sale |
8.45 |
2,686 |
22,697 |
420,047 |
| Rahmer Peter | See remarks |
Jan 27 '26 |
Sale |
7.62 |
11,684 |
89,032 |
277,964 |
| Rahmer Peter | See remarks |
Jan 28 '26 |
Sale |
8.45 |
1,354 |
11,441 |
276,610 |
| Catinazzo Thomas | Chief Financial Officer |
Jan 27 '26 |
Sale |
7.62 |
13,820 |
105,308 |
250,996 |
| Catinazzo Thomas | Chief Financial Officer |
Jan 28 '26 |
Sale |
8.45 |
1,695 |
14,323 |
249,301 |
| Patel Sanjiv | President and CEO |
Jan 06 '26 |
Sale |
7.82 |
43,168 |
337,574 |
661,041 |
| Patel Sanjiv | President and CEO |
Nov 03 '25 |
Sale |
7.00 |
62,073 |
434,511 |
703,215 |
| Rahmer Peter | See remarks |
Oct 29 '25 |
Sale |
7.50 |
21,394 |
160,455 |
337,469 |
| Rahmer Peter | See remarks |
Oct 28 '25 |
Sale |
7.29 |
19,135 |
139,494 |
358,863 |
| Catinazzo Thomas | Chief Financial Officer |
Oct 28 '25 |
Sale |
7.29 |
21,664 |
157,931 |
313,631 |
0.81%
0.77%
大文字化:
|
ボリューム (24 時間):